MX2012015021A - 5-(bifenil-4-il)-3-fenil-1, 2, 4-oxidiazolil derivados como ligandos en los receptores esfingosina-1-fosfato (s1p). - Google Patents

5-(bifenil-4-il)-3-fenil-1, 2, 4-oxidiazolil derivados como ligandos en los receptores esfingosina-1-fosfato (s1p).

Info

Publication number
MX2012015021A
MX2012015021A MX2012015021A MX2012015021A MX2012015021A MX 2012015021 A MX2012015021 A MX 2012015021A MX 2012015021 A MX2012015021 A MX 2012015021A MX 2012015021 A MX2012015021 A MX 2012015021A MX 2012015021 A MX2012015021 A MX 2012015021A
Authority
MX
Mexico
Prior art keywords
sphingosine
biphenyl
ligands
receptors
phenyl
Prior art date
Application number
MX2012015021A
Other languages
English (en)
Spanish (es)
Inventor
Anna Quattropani
Charles Baker-Glenn
Agnes Bombrun
Jerome Gonzalez
Jerome Dorbais
Chris Knight
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of MX2012015021A publication Critical patent/MX2012015021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012015021A 2010-07-08 2011-07-06 5-(bifenil-4-il)-3-fenil-1, 2, 4-oxidiazolil derivados como ligandos en los receptores esfingosina-1-fosfato (s1p). MX2012015021A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10168833 2010-07-08
US36274610P 2010-07-09 2010-07-09
PCT/EP2011/061372 WO2012004287A1 (en) 2010-07-08 2011-07-06 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors

Publications (1)

Publication Number Publication Date
MX2012015021A true MX2012015021A (es) 2013-04-03

Family

ID=42341535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015021A MX2012015021A (es) 2010-07-08 2011-07-06 5-(bifenil-4-il)-3-fenil-1, 2, 4-oxidiazolil derivados como ligandos en los receptores esfingosina-1-fosfato (s1p).

Country Status (15)

Country Link
US (1) US9029405B2 (enExample)
EP (1) EP2590956B1 (enExample)
JP (1) JP6014589B2 (enExample)
KR (1) KR20140003379A (enExample)
CN (1) CN103097365B (enExample)
AR (1) AR082132A1 (enExample)
AU (1) AU2011275854B2 (enExample)
CA (1) CA2804473C (enExample)
EA (1) EA201300092A1 (enExample)
ES (1) ES2586145T3 (enExample)
IL (1) IL224071B (enExample)
MX (1) MX2012015021A (enExample)
SG (1) SG186872A1 (enExample)
TW (1) TW201206429A (enExample)
WO (1) WO2012004287A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12571867B2 (en) 2022-04-14 2026-03-10 United States Pharmacopeial Convention Nuclear magnetic resonance analysis systems and methods

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
FI4081511T6 (fi) * 2019-12-23 2026-06-09 Sitryx Therapeutics Ltd Karboksijohdannaisia, joilla on anti-inflammatorisia ominaisuuksia
KR20220158743A (ko) * 2020-03-27 2022-12-01 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
US20240228448A1 (en) * 2021-03-31 2024-07-11 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (s1p1), imaging of s1p1, and processes for preparation thereof
WO2022220608A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711792B1 (de) 1994-11-05 1999-03-10 BASF Aktiengesellschaft Melaminharze
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
CN101522646A (zh) * 2006-09-29 2009-09-02 诺瓦提斯公司 具有抗炎和免疫抑制特性的二唑衍生物
CN101970420B (zh) 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物
TW201000099A (en) * 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12571867B2 (en) 2022-04-14 2026-03-10 United States Pharmacopeial Convention Nuclear magnetic resonance analysis systems and methods

Also Published As

Publication number Publication date
EA201300092A1 (ru) 2013-06-28
AU2011275854B2 (en) 2015-08-27
SG186872A1 (en) 2013-02-28
US9029405B2 (en) 2015-05-12
EP2590956B1 (en) 2016-05-04
JP2013530202A (ja) 2013-07-25
AR082132A1 (es) 2012-11-14
AU2011275854A1 (en) 2013-02-21
JP6014589B2 (ja) 2016-10-25
KR20140003379A (ko) 2014-01-09
IL224071B (en) 2018-06-28
CA2804473C (en) 2019-04-02
WO2012004287A1 (en) 2012-01-12
TW201206429A (en) 2012-02-16
US20130116289A1 (en) 2013-05-09
ES2586145T3 (es) 2016-10-11
CN103097365B (zh) 2016-02-24
CA2804473A1 (en) 2012-01-12
EP2590956A1 (en) 2013-05-15
CN103097365A (zh) 2013-05-08

Similar Documents

Publication Publication Date Title
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201170872A1 (ru) Ингибиторы протеинкиназы
MX340064B (es) Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos.
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
MX339873B (es) Inhibidores de serina/treonina cinasa.
BR112014010813A2 (pt) n-(tetrazol-5-il)-aril-carboxamidas e n-(triazol-5-il)-aril-carboxamidas substituídas em 5-fenilo e sua utilização como herbicidas
MX2009011155A (es) Derivados de indazol oxadiazol sustituidos para su uso como agonistas de esfingosina-1-fosfato (s1p).
MX377600B (es) Estimuladores de sgc.
MX2016008688A (es) Compuestos terapéuticos inhibidores.
UA115320C2 (uk) Інгібітори кінази
MX371353B (es) Compuestos heterociclicos aromaticos como compuestos antiinflamatorios.
MX2009009699A (es) Compuestos amino-5-[4-(difluorometoxi)fenil sustituidos]-5-fenilim idazolona como inhibidores de beta-secretasa.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2009005649A (es) Tratamiento para mieloma multiple.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
PH12014501278A1 (en) Kinase inhibitors
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
PH12016501096A1 (en) SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
NZ611169A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
EA201300092A1 (ru) Замещенные производные оксадиазола

Legal Events

Date Code Title Description
FA Abandonment or withdrawal